These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32885992)

  • 1. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
    Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
    Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignancy-related hypercalcemia developing on a bisphosphonate but responding to calcitonin.
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    Clin Lung Cancer; 2007 Jul; 8(7):434-5. PubMed ID: 17681097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
    McMahan J; Linneman T
    Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
    Thiébaud D; Jacquet AF; Burckhardt P
    Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.
    Wright JD; Tergas AI; Ananth CV; Burke WM; Hou JY; Chen L; Neugut AI; Richards CA; Hershman DL
    Cancer Invest; 2015; 33(8):331-9. PubMed ID: 26068056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
    Sekine M; Takami H
    Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Medical treatment of malignant hypercalcemia].
    Eto S; Nakano Y; Okada Y
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2311-8. PubMed ID: 8259844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
    Wimalawansa SJ
    Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
    Major P
    Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of bisphosphonate-resistant hypercalcemia of malignancy with calcitonin.
    Dawson C; Todd AM; Walton A
    J Palliat Med; 2014 Oct; 17(10):1084. PubMed ID: 25265187
    [No Abstract]   [Full Text] [Related]  

  • 12. Current management strategies for hypercalcemia.
    Pecherstorfer M; Brenner K; Zojer N
    Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Hypercalcemia in a Child With Acute Lymphoblastic Leukemia Relapse: Successful Management With Combination of Calcitonin and Bisphosphonate.
    Tagiyev A; Demirbilek H; Tavil B; Buyukyilmaz G; Gumruk F; Cetin M
    J Pediatr Hematol Oncol; 2016 Apr; 38(3):232-4. PubMed ID: 26907650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.
    Seisa MO; Nayfeh T; Hasan B; Firwana M; Saadi S; Mushannen A; Shah SH; Rajjoub NS; Farah MH; Prokop LJ; Wang Z; Fuleihan GE; Drake MT; Murad MH
    J Clin Endocrinol Metab; 2023 Feb; 108(3):585-591. PubMed ID: 36545700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
    Tai N; Inoue D
    Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients With Preexisting Renal Dysfunction.
    Palmer S; Tillman F; Sharma P; Auten J; Owen K; Clark SM; Morgan KP
    Ann Pharmacother; 2021 Mar; 55(3):303-310. PubMed ID: 32847379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.
    Fatemi S; Singer FR; Rude RK
    Calcif Tissue Int; 1992 Feb; 50(2):107-9. PubMed ID: 1571826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
    Major PP; Coleman RE
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
    Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
    Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of clodronate and calcitonin in hypercalcemia due to malignancy.
    Ljunghall S
    Recent Results Cancer Res; 1989; 116():40-5. PubMed ID: 2527399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.